Subarachnoid and Peripheral Nerve Block in a Patient with Charcot-Marie-Tooth Disease

Stinson T.  Ritter; Ryan J.  Jense; Joanna M.  Davies

doi:10.4236/ojanes.2013.31012

Stinson T. Ritter, Ryan J. Jense, Joanna M. Davies

Abstract: Charcot-Marie-Tooth disease (CMT) is a hereditary peripheral neuropathy characterized by progressive distal muscle weakness and wasting. If conservative treatment fails, or is not appropriately initiated, deformity, immobility and chronic pain may result. In severe cases, surgical intervention may be required. With the exception of case reports and case series, limited safety and efficacy data exists regarding the use of neuraxial and regional anesthesia for patients with CMT. This paper describes an anesthetic case report of a patient with CMT, and also provides a review of general and regional anesthetic considerations for this cohort. The purpose of this report is to highlight the potential benefits of neuraxial and regional anesthesia in patients with neuromuscular disorders, especially in settings where intra- and post-operative resources may be limited.

Keywords: Charcot-Marie-Tooth Disease; CMT; Regional Anesthesia; Neuraxial Anesthesia

Cite this paper: S. Ritter, R. Jense and J. Davies, "Subarachnoid and Peripheral Nerve Block in a Patient with Charcot-Marie-Tooth Disease," Open Journal of Anesthesiology, Vol. 3 No. 1, 2013, pp. 44-47. doi: 10.4236/ojanes.2013.31012.

References

[1] R. D. Miller, “Miller’s Anesthesia,” 7th Edition, Churchill Livingstone, Orlando, 2009.

[2] A. E. Emery, “Population Frequencies of Inherited Neuromuscular Diseases—A World Survey,” Neuromuscular Disorders, Vol. 1, No. 1, 1991, pp. 19-29. doi:10.1016/0960-8966(91)90039-U

[3] D. Kedlaya, “Physical Medicine and Rehabilitation for Charcot-Marie-Tooth Disease,” 2012. http://emedicine.medscape.com/article/315260

[4] B. Bissonnette, I. Luginbuehl, B. Marciniak, B. Dalens, “Syndromes: Rapid Recognition and Perioperative Implications,” McGraw-Hill, New York, 2006, pp. 153-155.

[5] J. Burns, P. Bray, L. A. Cross, K. N. North, M. M. Ryan and R. A. Ouvrier, “Hand Involvement in Children with Charcot-Marie-Tooth Disease Type 1A,” Neuromuscular Disorders, Vol. 18, No. 12, 2008, pp. 970-973. doi:10.1016/j.nmd.2008.08.004

[6] E. M. Yiu, N. Geevasinga, G. A. Nicholson, E. R. Fagan, M. M. Ryan and R. A. Ouvrier, “A Retrospective Review of X-Linked Charcot-Marie-Tooth Disease in Childhood,” Neurology. Vol. 76, No. 5, 2011, pp. 461-466. doi:10.1212/WNL.0b013e31820a0ceb

[7] B. G. Kousseff, T. A. Hadro, D. L. Treiber, T. Wollner and C. Morris, “Charcot-Marie-Tooth Disease with Sensorineural Hearing Loss—An Autosomal Dominant Trait,” Birth Defects Original Article Series, Vol. 18, No. 3B, 1982, pp. 223-228.

[8] T. Stojkovic, P. Latour, A. Vandenberghe, J. F. Hurtevent and P. Vermersch, “Sensorineural Deafness in X-Linked Charcot-Marie-Tooth Disease with Connexin 32 Mutation (R142Q),” Neurology, Vol. 52, No. 4, 1999, pp. 1010 1014. doi:10.1212/WNL.52.5.1010

[9] T. Sevilla, et al., “Vocal Cord Paresis and Diaphragmatic Dysfunction Are Severe and Frequent Symptoms of GDAP1-Associated Neuropathy,” Brain, Vol. 131, No. 11, 2008, pp. 3051-3061. doi:10.1093/brain/awn228

[10] J. Burns, R. A. Ouvrier, E. M. Yiu and M. M. Ryan, “Extended Treatment of Childhood Charcot-Marie-Tooth Disease with High-Dose Ascorbic Acid,” Journal of the Peripheral Nervous System, Vol. 16, No. 3, 2011, pp. 272 274. doi:10.1111/j.1529-8027.2011.00348.x

[11] J. Bradbury, “Antiprogesterone Hope for Inherited Neuropathy,” The Lancet Neurology, Vol. 3, No. 1, 2004, p. 6. doi:10.1016/S1474-4422(03)00636-7

[12] J. F. Antognini, “Anaesthesia for Charcot-Marie-Tooth Disease: A Review of 86 Cases,” Canadian Journal of Anesthesia, Vol. 39, No. 4, 1992, pp. 398-400. doi:10.1007/BF03009054

[13] H. J. Schmitt, S. Wick and T. Münster, “Onset and Duration of Mivacurium-Induced Neuromuscular Blockade in Children with Charcot-Marie-Tooth Disease. A Case Series with Five Children,” Paediatric Anaesthesia, Vol. 16, No. 2, 2006, pp. 182-187. doi:10.1111/j.1460-9592.2005.01627.x

[14] A. S. Baraka, “Vecuronium Neuromuscular Block in a Patient with Charcot-Marie-Tooth Syndrome,” Anesthesia & Analgesia, Vol. 84, No. 4, 1997, pp. 927-928.

[15] D. Pogson, J. Telfer and S. Wimbush, “Prolonged Vecu ronium Neuromuscular Blockade Associated with Charcot Marie Tooth Neuropathy,” British Journal of Anaesthesia, Vol. 85, No. 6, 2000, pp. 914-917. doi:10.1093/bja/85.6.914

[16] M. Brock, C. Guinn and M. Jones, “Anesthetic Management of an Obstetric Patient with Charcot-Marie-Tooth Disease: A Case Study,” American Association of Nurse Anesthetists, Vol. 77, No. 5, 2009, pp. 335-337.

[17] S. Dhir, S. Balasubramanian and D. Ross, “Ultrasound Guided Peripheral Regional Blockade in Patients with Charcot-Marie-Tooth Disease: A Review of Three Cases,” Canadian Journal of Anesthesia, Vol. 55, No. 8, 2008, pp. 515-520. Vol. 77, No. 5, 2009, pp. 335-337.

[18] A. Bosenberg and K. Larkin, “Anaesthesia and Charcot Marie-Tooth Disease,” Southern African Journal of Anaesthesia & Analgesia, Vol. 12, No. 4, 2006, pp. 131-133.